Clarivate LogoElsevier Logo

Market & Financial Intelligence Platforms · vs · Print Press & Magazine Publishing

Clarivate vs Elsevier

Structured technology and market comparison · 2026

Direct Feature Comparison

Clarivate · vs · Elsevier
Direct Feature Comparison: Clarivate vs Elsevier
Attribute
Clarivate LogoClarivate
Elsevier LogoElsevier
Market Cluster / SectorMarket & Financial Intelligence PlatformsPrint Press & Magazine Publishing
Business Model / RoleData Provider / BrokerPublisher & Media Owner · B2B SaaS Provider
Platform FocusResearch, library and IP workflow software and data provider.Scientific publishing and research intelligence platform for institutions and professionals.
Company Size>5,000 employees>5,000 employees
HeadquartersUnited KingdomNetherlands
Year Founded20191880
Dossier & Alternatives

Analyze all overlapping signals and tech stacks for Clarivate and Elsevier

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between Clarivate and Elsevier?

Clarivate and Elsevier are enterprise-focused research-information firms serving libraries, academic institutions, and IP-dependent organizations. Both offer discovery, analytics and subscription workflows, but Clarivate emphasizes curated indexes, IP management and cross-product workflow integrations, while Elsevier anchors on proprietary journal content plus publishing services and clinical/scientific decision tools. Clarivate differentiates on IP and curated indices; Elsevier on content ownership and publishing ecosystem.

How do the features of Clarivate and Elsevier compare?

Product-wise, both vendors supply discovery, bibliometrics and institutional analytics—Clarivate via curated indices, Web of Science, InCites and IP-focused tools (Derwent, patent analytics, EndNote), Elsevier via Scopus/ScienceDirect, SciVal, Mendeley and clinical/publishing platforms. Overlap occurs in citation metrics and analytics; Clarivate adds deeper patent/IP workflow and curated index granularity, while Elsevier provides broader full-text access, publishing services and clinical decision support.

What are the top alternatives to Clarivate and Elsevier?

When evaluating Clarivate and Elsevier, enterprise buyers also consider other platforms in Measurement & Analytics Platform and Productivity & Collaboration SaaS. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of Clarivate and Elsevier compare?

Clarivate is headquartered in United Kingdom (founded in 2019) with >5,000 employees. Elsevier is based in Netherlands (founded in 1880) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: Clarivate vs Elsevier

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

Clarivate Logo

Clarivate

Recent Signals

  • ·SEC APIM&A & Corporate Finance

    Clarivate Announces Expiration and Results of Debt Tender Offers

    On November 12, 2026, Clarivate Plc filed a Form 8-K under Item 8.01 announcing the expiration and final results of previously initiated cash tender offers for certain debt securities. The tender offers were executed through its wholly-owned subsidiary, Clarivate Science Holdings Corporation. The filing incorporates a press release detailing the conclusion of the debt retirement program, supporting the company's broader balance sheet and capital structure management.

    • Clarivate announced the expiration and results of cash tender offers for specific debt securities on November 12, 2026.
    • The tender offers were conducted via its wholly-owned subsidiary, Clarivate Science Holdings Corporation.
    • Details of the accepted tenders and final debt retirement were released via Exhibit 99.1.
  • ·SEC APIM&A & Corporate Finance

    Clarivate Announces Cash Tender Offer for Outstanding Subsidiary Debt Securities

    On September 17, 2026, Clarivate Plc announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation, launched a cash tender offer to purchase certain of its outstanding debt securities. The transaction represents an active liability management initiative aimed at optimizing the company's capital structure and debt profile. Further financial terms and specific tranches targeted in the tender offer were disclosed via an accompanying press release filed as Exhibit 99.1.

    • Clarivate Science Holdings Corporation, a wholly-owned subsidiary of Clarivate Plc, initiated a cash tender offer for selected debt securities on September 17, 2026.
    • The filing was submitted under Item 8.01 (Other Events) accompanied by a press release as Exhibit 99.1.
    • The corporate action is aimed at liability management and refinancing debt obligations.
  • ·SEC APIM&A & Corporate Finance

    Clarivate Completes $600M Sale of Life Sciences and Healthcare Unit to Altaris

    On October 6, 2026, Clarivate completed the divestiture of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC, pursuant to a July 2026 purchase agreement. Total consideration consists of $500 million in cash at closing (subject to customary working capital and debt adjustments), an unsecured senior note of $75 million issued by a Buyer affiliate, and up to $25 million in deferred consideration payable no later than January 31, 2028 upon conclusion of transition services. Concurrent with the divestment, Henry Levy terminated his role as President of Life Sciences & Healthcare under a separation agreement.

    • Clarivate closed the divestiture of its Life Sciences and Healthcare segment to Altaris affiliate Janus Buyer, LP on October 6, 2026.
    • Consideration includes $500 million cash at closing, a $75 million unsecured senior note, and $25 million in deferred consideration payable by January 31, 2028.
    • Henry Levy stepped down as President, Life Sciences & Healthcare upon closing under a formal separation agreement.
Elsevier Logo

Elsevier

Recent Signals

No recent market signals documented for Elsevier in the current tracking window.

Start with a company or market. Track what changes.

Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.